{
    "2019-11-01": [
        [
            {
                "time": "2019-09-30",
                "original_text": "WeWork IPO was a Failure â€“ These 2 IPO Stocks are Surging",
                "features": {
                    "keywords": [
                        "WeWork",
                        "IPO",
                        "Failure",
                        "Surging"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "real estate",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-10-22",
                "original_text": "The Good, Bad, and Ugly for Biogen Stock",
                "features": {
                    "keywords": [
                        "Good",
                        "Bad",
                        "Ugly",
                        "Biogen"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2019-11-05",
                "original_text": "Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss",
                "features": {
                    "keywords": [
                        "Agios",
                        "Q3",
                        "Loss",
                        "Narrower",
                        "Revenues",
                        "Miss"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-11-14",
                "original_text": "UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "2019",
                        "sales",
                        "outlook",
                        "new drugs",
                        "excel"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}